Clinical Trials · NCT00111540
Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 456
- Start date
- Nov 2002
- Locations
- 60 sites, United States
- Primary endpoint
- Change in HbA1c (glycosylated hemoglobin) from Visit 1 to each protocol visit